# Intravitreal Infliximab for Diabetic Macular Edema (DME) and Choroidal Neovascularization (CNV)

> **NCT00695682** · PHASE1 · UNKNOWN · sponsor: **Retina Research Foundation** · enrollment: 4 (estimated)

## Conditions studied

- Diabetic Retinopathy
- Macular Degeneration

## Interventions

- **DRUG:** intravitreal injection of infliximab

## Key facts

- **NCT ID:** NCT00695682
- **Lead sponsor:** Retina Research Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-06
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 4 (ESTIMATED)
- **Last updated:** 2008-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00695682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00695682, "Intravitreal Infliximab for Diabetic Macular Edema (DME) and Choroidal Neovascularization (CNV)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00695682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*